Long et al. [146] developed a novel delivery system of RGD-conjugated resveratrol human serum albumin (HAS) nanoparticles (RGD-RVT-HSA NPs) for ovarian cancer therapy. The gene discussed is ALB; the disease is ovarian carcinoma.